BORTEZOMIB
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1
Hikma Pharmaceuticals USA
Drug class
Antineoplastic - Proteasome Enzyme Inhibitors
Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex. Read more about Antineoplastic - Proteasome Enzyme Inhibitors
22 drugs in this class 21 manufacturers
Drugs in Antineoplastic - Proteasome Enzyme Inhibitors
BORTEZOMIB
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1
Pfizer Laboratories
BORTEZOMIB
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1
GLAND PHARMA LI
BORTEZOMIB
ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1
AVENACY, INC
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Proteasome Enzyme Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex.
By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells.
This therapeutic class is primarily indicated for the treatment of hematologic malignancies, serving as a foundational component in regimens for multiple myeloma and mantle cell lymphoma.
-
fpnotebook.com
Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells
-
nih.gov
Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex
-
rxlist.com
By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells This therapeutic class is primarily indicated for the treatment of hematologic malignancies, serving as a foundational component in regimens for multiple myeloma and mantle cell lymphoma
-
patsnap.com
By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells
-
fda.gov
This therapeutic class is primarily indicated for the treatment of hematologic malignancies, serving as a foundational component in regimens for multiple myeloma and mantle cell lymphoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.